Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

IntelGenx Technologies Corp. (IGXT)

Add IGXT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator GaryJPalys, kyouter
Search This Board:
Last Post: 10/21/2014 7:42:24 PM - Followers: 184 - Board type: Free - Posts Today: 16

IntelGenx Technologies Corp

Listing Exchanges: OTCQX as IGXT and Toronto Venture Exchange: IGX.V

Current partners include, Edgemont Pharma, Pacific Therapeutics, Dava Pharmaceuticals, RedHill Biopharma, and PAR Pharmaceuticals. We are in discussions with other potential partners for some of our other products.

Our unique proprietary platform delivery technologies offer many benefits to our partners including:
Broad range of delivery profiles
Convenient and versatile products
High quality products

Business Strategy
Our business strategy is to apply our drug delivery technologies to improve existing drug compounds with proven efficacy and safety and, in conjunction with
strategic development and distribution partners, reintroduce these drug compounds to the market as branded products with improved deliverability and efficacy. 

Because we are developing improved formulations of currently marketed therapeutics, our products typically require fewer clinical trials to generate the safety and
efficacy data needed to achieve regulatory approval than drug formulations that have not been previously marketed. As a result, we believe we can accelerate
development and reduce risk compared to traditional pharmaceutical and biotechnology companies. 

Using the 505(b)(2) approach to obtain FDA approval, our products have the possibility of obtaining  three years of market exclusivity.


IntelGenx (IGX / IGXT) Announces Commercial Launch of Forfivo XL(TM) in USA - Viral News

(Click the link below to watch video)

    Forfivotm XL Launch Video


(Click on picture below to go to website)


Friday, October 5, 2012

Withdrawal of Teva's Budeprion XL 300 from the US market should benefit IntelGenx Technologies

USFDA has asked Teva to wihdraw - Budeprion XL 300 from the US.
  According to USFDA, Budeprion XL 300 is no bioequivalent to Welbutrin XL 300.
  It has been found that Budeprion XL 300 releases the active ingredient faster than the original drug Welbutrin XL 300.
The USFDA reviewed the Budeprion XL, after several patients complained 
about head aches, anxiety and insomnia.

We think the withdrawal can be positive for IntelGenx
which is preparing to launchForfivo ( bupropion extended release 450mg)
and should help the launch trajectory for Forfivo. 
Forfivo will be marketed by Edgemont pharmaceuticals in the US.
Edgemont focuses exclusively on launching specialty drugs aimed at the neuropsychiatry sector,
and has one drug on the market - high-dose fluoxetine (Prozac).

Forfivo is the only single tablet that is formulated to deliver a dose of 450mg.
Until now, those patients who need to take the highest dose (450mg)
of bupropion XL need to take multiple tablets of lower-strength doses as there.

Market Opportunity

In 2011, total branded and generic sales of extended-release bupropion
totaled $745 million, of which 
roughly 20% was for the highest dose (450mg).


IntelGenX Corporate Presentation June 2014

Click on the image below
June, 2014



                                     The archive for all Intelgenx Presentations from 2007 to 2014 can be found here:


March 12th, 2012 -   Cleland Fund comments regarding their investment insight for IGXT: 

March 12, 2012 -   BluMont Capital Corporation - Northern Rivers Funds - 70 University Avenue - Suite 1200, PO Box 16 - Toronto, ON M5J 2M4 - Canada - Tel: 416.597.1226 - Fax: 416.597.8926

The Northern Rivers Innovation RSP Fund ("the Innovation Fund" or "the Fund") Dear Partners and Friends: Let's go through the major holdings…(Below is just the IGXT portion)

INTELGENX: FDA approval for their 1st drug in November + a commercialization partner for that drug + a deal with Par Pharmaceuticals = lower share price??? This is a completely irrational situation, making IntelGenx a table pounder. As of the close on March 7, the stock is LOWER than it was before CPI-300 (IntelGenx' antidepressant) received FDA approval; LOWER than it was before the deal with Par Pharmaceutical; and LOWER than it was before the announcement of its commercialization partner for CPI-300. I would argue that at $0.55 or lower, the only thing an investor is paying for is CPI-300, meaning that you are getting the entire thin-film delivery platform and 9 drug pipelines for FREE. Notably, there are only a handful of thin-film companies out there, and IntelGenx is one of only two that are publicly traded (that I am aware of). As thin-films become more recognized for their value to big pharma over the coming years, the scarcity value of thin-film platforms will ultimately result in IntelGenx' thin-film platform and pipeline receiving a premium valuation; right now, there is NO value. Ridiculous. I have put my money where my mouth is recently, and bought shares in the open market for the second of the two funds I run. To a certain degree, however, I understand what has happened: there was (unbeknownst to me or management) a scummy promote on IntelGenx last summer, in which CPI-300 was hyped as a billion dollar drug. Anyone who knows anything about CPI-300 and its market knows that that is complete crap. In fact, CPI-300 is the smallest revenue potential drug within IntelGenx' pipeline, with peak revenue to Intelgenx' commercialization partner maybe in the $60-$100million range. This means that reality has been a big let-down to those who bought into the billion dollar dream. But the fact is that the commercialization deal and FDA approval for CPI-300 do two very important things for IntelGenx: 1) Getting CPI-300 approved by the FDA provided concrete illustration that IntelGenx has the skill set to negotiate the 505b2 pathway to drug approval, which involves both dealing with the FDA and dealing with the court system. For me, that validation will ultimately lower the discount rate that is applied to the rest of IntelGenx' pipeline. 2) The upfront, milestone and royalty payments from the commercialization deal for CPI-300 arguably cover all of IntelGenx' development costs for its pipeline of thin-film 505b2 drugs. If this sounds far-fetched, recall that the 505b2 pathway to drug approval is dramatically different than the conventional PhaseI-II-III pathway, because IntelGenx is simply moving existing, already-FDA-approved drugs onto a different delivery platform. i.e., IntelGenx is working on projects such as moving Cialis and a migraine drug onto a thin-film platform. It is a cheap, and extremely low-risk pathway to getting a drug to market. The CPI-300 deal with Edgemont Pharmaceuticals: a source of disappointment for the market; a source of confidence for me On February 14, IntelGenx announced a commercial license agreement for CPI-300 with Edgemont Pharmaceuticals. The deal provided for $1M upfront for IntelGenx and a series of milestones that could reach $28.5M over the life of the agreement. According to the company up to $4M of these milestones are achievable at the product launch or shortly thereafter. IntelGenx is also entitled to a double digit royalty on net product sales. The market reaction thus far to the deal has been negative. It seems many people were perhaps speculating on a more prominent partner and/or better economics in the deal. However, I think the markets have misinterpreted the quality of the deal, I think in part due to misjudging Edgemont but also misunderstanding what CPI-300 means to IntelGenx. On the former, Edgemont is a smaller private company that has very little visibility to people outside the industry. But a closer inspection reveals a company with a sales and marketing focus on neurology, a CEO who formerly ran Novartis' CNS business in the US, and a Board populated with people from some of the most successful U.S. specialty pharma companies of the past 15 years. This last point is one of the nuances that the markets really seem to have missed. Two of the Edgemont Board members are former Kos Pharmaceuticals (formerly Nasdaq: KOSP) executives who now work for a private equity firm called Vatera Capital. For anyone who hasn't heard of Kos, they were arguably the most successful specialty pharma company in the U.S. in the past 15 years. They created a market for a prescription vitamin called Niaspan, which paved the way for future prescription vitamin and omega-3 companies like Reliant, Amarin and Neptune/Acasti. Kos was eventually bought by Abbott for $3.7B, and one of the founders Michael Jaharis took his money (he is estimated now to be worth $1.9B) and formed Vatera Capital to invest in businesses like Edgemont. So Vatera's investment in Edgemont gives me tremendous confidence that IntelGenx has landed a great partner who has the marketing savvy and financial backing to extract the most value out of CPI-300. That leads me to my second point regarding the significance of this deal to IntelGenx: In my opinion CPI-300 will provide IntelGenx the financial platform to aggressively accelerate and expand its pharmaceutical thin-film business. Thin-films are the big opportunity in IntelGenx' portfolio. Whether it is drugs for erectile dysfunction, insomnia or migraine, each of these products represent bigger opportunities for IntelGenx than CPI-300. With Reckitt Benckiser's suboxone film (one of only two FDA approved thin films) apparently trending toward $1B in annual sales, it is clear that the market and FDA are receptive to this new delivery system. Fortunately IntelGenx has a number of products through pilot human studies and one product (migraine) due to enter pivotal studies shortly, so they would appear to be well positioned with a number of nearer term thin-film projects. With all this in mind, I believe that Edgemont and CPI-300 provide a means to a much more lucrative end, that being IntelGenx becoming the world leader in the growing area of thin film drug delivery and development.


                                                                                                                                                                                  The following info is now based on IGXT's own SEC filings

Industry: Bio-technology

Market Capitalization: 26.66 Million 

Issued Shares: 63.1 Million

Fully Diluted Shares: 72 Million

Float Shares: 56.9 Million

Insider and Institutional Ownership: 18% 


Latest News

  •                                                                                                                                                                                                                                                                        (Click on Date for link to news article)

Intelgenx Announces Management Changes


Intelgenx Announces Equity Analyst Coverage by H.C. Wainwright


Intelgenx and RedHill Biopharma Report Positive Bioavailability Study Results in Support of Planned European Marketing Application in Q3/2014 for Anti-Migraine VersaFilm(TM) Product


Intelgenx Reports Q1 2014 results and provides corporate developement update


Intelgenx Announces government of canada funding for cNS VersaFilm(TM) project


Intelgenx and Redhill Biopharma Announce Commencement of a Bioavailability Study with Anti-Migraine VersaFilm(TM) Product to support european marketing application planned for q3/2014



and RedHill Biopharma Provide an Update on FDA's Ongoing Review of the NDA for Migraine VersaFilm(TM) Product


Intelgenx Announces Receipt of an Additional U.S. Patent Allowance Related To Proprietary Technology


Intelgenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines


Intelgenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm


IntelGenx Announces Additional Developement and Commercialization with Par for Two More Products


IntelGenx Corp. Receives Buprenorphine/Naloxone Sublingual Film Product Patent Infringement Complaint


IntelGenx Receives Paragraph IV Certification Letter on Submission of ANDA for Forfivo XL™


IntelGenx Reports Q2, 2013 Results and Corporate Development Highlights


Time To Revalue IntelGenx- 2 More Products Being Reviewed By The FDA For Approval



Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction


Small-Cap Biotechs with Blockbuster Potential: Hugh Cleland


IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product


IntelGenx Reports Q1, 2013 Results and Provides Operational Update


IntelGenx secures leadership Succession


IntelGenx submits New Drug Application for Anti-Migraine VersaFilm(TM)


IntelGenx Announces Commercial Launch of Forfivo XL(TM) in USA


  IntelGenx Reports Second Quarter 2012 Results and Highlights Recent Developments


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
IGXT News: Current Report Filing (8-k) 10/02/2014 08:10:28 AM
IGXT News: Current Report Filing (8-k) 10/01/2014 08:18:11 AM
IGXT News: Current Report Filing (8-k) 09/17/2014 10:01:01 AM
IGXT News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 09/04/2014 01:14:18 PM
IGXT News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 09/04/2014 01:12:20 PM
#10861  Sticky Note This Small Cap Is Poised To Tap Multi-Billion GaryJPalys 10/20/14 04:33:21 AM
#10517  Sticky Note IntelGenx (TSX-V:IGX) (OTCQX:IGXT) and RedHill Biopharma Report Stockmountie 05/21/14 08:09:54 AM
#10880   New September presentation. mjg24718 10/21/14 07:42:24 PM
#10878   Woohoo a $29.40 buy got ya above to ofspring 10/21/14 03:47:26 PM
#10877   Ofspring. I have to say your giving much Polonia 10/21/14 03:43:14 PM
#10875   More debt less revenue spells more dilution on ofspring 10/21/14 03:11:23 PM
#10874   This is held up by pure speculation lol ofspring 10/21/14 03:03:10 PM
#10873   You sound scared, and should be. specular 10/21/14 02:57:28 PM
#10872   56 shareholders on this bloated pig with a ofspring 10/21/14 12:57:05 PM
#10871   This garbage pipedream stock has done nothing but ofspring 10/21/14 12:52:15 PM
#10869   Even the insiders dont want this garbage lol.... ofspring 10/21/14 11:50:59 AM
#10868   Nobody's buying this garbage and holding lol... Look ofspring 10/21/14 11:45:57 AM
#10867   These medical drug companies are garbage... PIPEDREAM ofspring 10/21/14 11:36:41 AM
#10866   Once again let me remind you IGXT has specular 10/21/14 11:32:01 AM
#10865   Looks like a POS pipedream overpriced small cap ofspring 10/21/14 11:19:27 AM
#10864   That was brought up back in 2011... Horst GaryJPalys 10/20/14 05:01:29 PM
#10863   Horst has disclosed that there is no relation. killers_420 10/20/14 04:42:17 PM
#10862 Dr. Robert L. Zerbe, MD Polonia 10/20/14 01:29:58 PM
#10861   This Small Cap Is Poised To Tap Multi-Billion GaryJPalys 10/20/14 04:33:21 AM
#10860   Article discussed below is now available. Polonia 10/19/14 12:20:26 PM
#10859   Probably Horst himself! LOL GaryJPalys 10/17/14 09:58:02 AM
#10858   No, Intelgenx went down into the 0.30's the GaryJPalys 10/17/14 09:56:25 AM
#10857   Horst may be "business challenged" - chemist72 10/17/14 09:45:46 AM
#10856   Unfortunately no I didn't see it yesterday. specular 10/17/14 09:16:10 AM
#10855   Hah, maybe that's why IGXT went into the chemist72 10/17/14 09:01:24 AM
#10854   Anyone see this article about Intelgenx before it GaryJPalys 10/17/14 02:40:29 AM
#10853   Thanks Chemist :) I put a measly $390 GaryJPalys 10/16/14 04:20:35 PM
#10851   Well the other reality - that you conveniently specular 10/16/14 02:17:06 PM
#10850   Gary, welcome back as an IGXT shareholder - chemist72 10/16/14 01:50:40 PM
#10849   Read the company press release on Q3 2013 quimper27 10/16/14 11:42:23 AM
#10848   Gross profit down total revenue down debt up ofspring 10/16/14 11:41:10 AM
#10847   Looks like a saw on the chart downward ofspring 10/16/14 11:36:31 AM
#10846   Looks like its heading right where it belongs .08 ofspring 10/16/14 11:07:47 AM
#10845   Yea gary it should go alot lower... Book ofspring 10/16/14 11:01:03 AM
#10844   I bought a very small amount today... 1,000 GaryJPalys 10/15/14 07:04:53 PM
#10843   Hello! Polonia 10/15/14 04:42:50 PM
#10842   You're absolutely right Quimper! GaryJPalys 10/15/14 04:23:31 PM
#10841   thought never say this...but kyouter 10/15/14 12:26:05 PM
#10840   Actually no. They were not the first to quimper27 10/15/14 11:23:14 AM
#10839   Well guys. Buy when nobody else does it Polonia 10/15/14 10:44:56 AM
#10838   Add in the dilution and it's 5 years. specular 10/14/14 05:05:45 PM
#10837   You have to go all the way back GaryJPalys 10/14/14 04:09:15 PM
#10836   It's a real shame that Horst is back GaryJPalys 10/14/14 03:26:50 PM
#10835   I'm afraid you will have to do your GaryJPalys 10/13/14 07:19:45 PM
#10834   Chemist72. Do you have any stocks? Polonia 10/13/14 01:27:16 PM
#10833   Yes Gary, I asked about the film technology. Polonia 10/13/14 01:07:55 PM
#10832   You were talking about the film technology as GaryJPalys 10/13/14 10:52:09 AM
#10831   Thanks Polonia - nice to have another perspective chemist72 10/13/14 08:30:22 AM
#10830   Hi Gary, NO NO NO its not three Polonia 10/12/14 02:40:42 PM
#10829   3 different substances... As far as the Reckitt GaryJPalys 10/12/14 11:31:16 AM
#10828   Post #10826 was removed because it was a GaryJPalys 10/12/14 11:28:04 AM
#10827   IGXT Three players. MonoSolRx, Biodelivery sciences and Intelgenx Polonia 10/12/14 07:40:55 AM